Abstract
Background: Bionanomaterials create new opportunities for advancing medical sciences and diseases treatment in relation to human health care. Innovations in the use of such nanomaterials and nanodevices can lead to significant improvements in the use of drugs/devices.
Objective: The present study attempts to analyse patenting trends in different areas and compare the patentability criteria and the disclosure norms for nanobiotechnology inventions in countries such as US, EU and India in the field of diagnostics and therapeutics. Method: Nanobiotechnology patents were identified based on the search using IPC/CPC as well as keywords conducted on Relecura (a web-based patent and portfolio analysis platform). Growth of filing/ grants and by area was analysed. Comparative analysis of the patentability criteria was done to identify challenges in prosecution of nanobiotechnology applications. Result: US, China, followed by Europe are top patent filing countries in nanobiotechnology. Topic maps indicate medicinal preparations to be the major area of patenting. There is an increase in patenting in BRIC since 2000. The assessment of novelty, inventive step and specific disclosure norms in different jurisdictions related to nanobiotechnology inventions reveal challenges in patent prosecution. Conclusion: 79% of the overall nanobiotechnology patents are from the medicinal preparation area followed by a significant number in case of diagnostic and surgical applications. The upward trend in patenting indicates to the potential of inventions in the field of diagnostics. The development of objective and subjective criteria with respect to patentability indicates to elaborate patent office practice and prosecution in this area.Keywords: Nanobiotechnology, nanomedicine, patent, disclosure norms, gene splicing, therapeutics.
Graphical Abstract
Recent Patents on Biotechnology
Title:Patents in Nanobiotechnology: A Cross Jurisdictional Approach
Volume: 11 Issue: 1
Author(s): Padmavati Manchikanti*, Shailaja Uppala and Ramesh Kumar Bonta
Affiliation:
- Rajiv Gandhi School of IP Law, IIT Kharagpur, Kharagpur-721302, West Bengal,India
Keywords: Nanobiotechnology, nanomedicine, patent, disclosure norms, gene splicing, therapeutics.
Abstract: Background: Bionanomaterials create new opportunities for advancing medical sciences and diseases treatment in relation to human health care. Innovations in the use of such nanomaterials and nanodevices can lead to significant improvements in the use of drugs/devices.
Objective: The present study attempts to analyse patenting trends in different areas and compare the patentability criteria and the disclosure norms for nanobiotechnology inventions in countries such as US, EU and India in the field of diagnostics and therapeutics. Method: Nanobiotechnology patents were identified based on the search using IPC/CPC as well as keywords conducted on Relecura (a web-based patent and portfolio analysis platform). Growth of filing/ grants and by area was analysed. Comparative analysis of the patentability criteria was done to identify challenges in prosecution of nanobiotechnology applications. Result: US, China, followed by Europe are top patent filing countries in nanobiotechnology. Topic maps indicate medicinal preparations to be the major area of patenting. There is an increase in patenting in BRIC since 2000. The assessment of novelty, inventive step and specific disclosure norms in different jurisdictions related to nanobiotechnology inventions reveal challenges in patent prosecution. Conclusion: 79% of the overall nanobiotechnology patents are from the medicinal preparation area followed by a significant number in case of diagnostic and surgical applications. The upward trend in patenting indicates to the potential of inventions in the field of diagnostics. The development of objective and subjective criteria with respect to patentability indicates to elaborate patent office practice and prosecution in this area.Export Options
About this article
Cite this article as:
Manchikanti Padmavati*, Uppala Shailaja and Bonta Kumar Ramesh, Patents in Nanobiotechnology: A Cross Jurisdictional Approach, Recent Patents on Biotechnology 2017; 11 (1) . https://dx.doi.org/10.2174/1872208310666161123100223
DOI https://dx.doi.org/10.2174/1872208310666161123100223 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Spectral Characterization, Antibacterial and Anticancer Activity of some Titanium Complexes
Anti-Cancer Agents in Medicinal Chemistry Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry Targeting Thioredoxin Reductase: Anticancer Agents and Chemopreventive Compounds
Medicinal Chemistry Membrane Localization of Estrogen Receptors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bioactive Proteins and Peptides from Soybeans
Recent Patents on Food, Nutrition & Agriculture Transcriptionally Targeted Adenovirus Vectors
Current Gene Therapy Can We Predict the Sites of the Recurrence of Ovarian Cancer by F-18 FDG PET/CT Depending on CA-125 Level?
Current Medical Imaging Chemistry and Structural Evaluation of Different Phospholipase A2 Inhibitors in Arachidonic Acid Pathway Mediated Inflammation and Snake Venom Toxicity
Current Topics in Medicinal Chemistry Clinical Application of Sorafenib for Treating Hepatocellular Carcinoma and Beyond
Clinical Cancer Drugs Discovery of Novel <i>N</i>-alkyl 4-anilinofuro[2,3-<i>b</i>]quinoline Derivatives (CIL-102 Derivatives) Against Castration-resistant Human Prostate Cancers
Anti-Cancer Agents in Medicinal Chemistry Meet Our Section Editor:
Current Medicinal Chemistry Receptor Specific Macrophage Targeting by Mannose-Conjugated Gelatin Nanoparticles- An In Vitro and In Vivo Study
Current Nanoscience Heparan Sulphate Proteoglycans and Viral Vectors : Ally or Foe?
Current Gene Therapy Quinone Bioreductive Prodrugs as Delivery Agents
Current Drug Delivery Chemical Constituents of Plants from the Genus Valeriana
Mini-Reviews in Organic Chemistry The MYCN Oncogene as a Specific and Selective Drug Target for Peripheral and Central Nervous System Tumors
Current Cancer Drug Targets Differences in Vanadocene Dichloride and Cisplatin Effect on MOLT-4 Leukemia and Human Peripheral Blood Mononuclear Cells
Medicinal Chemistry Evaluation of the Soluble Pectin Content in Culinary Preparations
Current Nutrition & Food Science Tyrosine Kinase Mutations in Human Cancer
Current Molecular Medicine